|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
We performed integrative analysis for 3 sets of prostate cancer (PCa) genomic data, and found that BMI1 and androgen receptor (AR) were positively correlated, suggesting that AR might regulate BMI1.
|
31462713 |
2020 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Both hormone-sensitive and castration- and enzalutamide-resistant prostate cancers (PCa) depend on the ternary complex factor (TCF) protein ELK1 to serve as a tethering protein for the androgen receptor (AR) to activate a critical set of growth genes.
|
31794091 |
2020 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this review, we will provide a comprehensive view of the effects of taxanes on androgen receptor signaling in prostate cancer.
|
29900882 |
2020 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling plays a central role in metabolic reprogramming for prostate cancer (PCa) growth and progression.
|
31838085 |
2020 |
|
Androgen-Insensitivity Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
This is the first case that AIS was caused by de novo mutation of AR in a 46, XY Disorder of Sexual Development (DSD) patient by the assisted reproduction technique (ART).
|
31429517 |
2019 |
|
Androgen-Insensitivity Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
A novel de novo c.1669_1670insC insertion in the AR gene caused androgen insensitivity syndrome.
|
31401253 |
2019 |
|
Androgen-Insensitivity Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Androgen insensitivity syndrome (AIS), a rare X-linked recessive genetic disorder with a normal 46, XY karyotype, is caused by defect of androgen receptor gene (AR) leading to resistance of the target tissues to androgenic hormones.
|
30742848 |
2019 |
|
Androgen-Insensitivity Syndrome
|
1.000 |
Biomarker
|
disease |
BEFREE |
According to the grade of the remaining androgen receptor (AR) function, AIS is classified as complete (CAIS), partial (PAIS) or mild (MAIS).
|
31351520 |
2019 |
|
Androgen-Insensitivity Syndrome
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Androgen insensitivity syndrome (AIS) is a congenital disorder in which a defect in the androgen receptor (AR) gene leads to cellular resistance to androgens.
|
30449224 |
2019 |
|
Androgen-Insensitivity Syndrome
|
1.000 |
Biomarker
|
disease |
BEFREE |
Our study expands the spectrum of AR gene mutations and confirms the usefulness of AR gene sequencing to support a diagnosis of AIS and to enable prenatal or antenatal screening.
|
29785970 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Therefore, this review aims to summarize the tumor microenvironment and its impact on androgen receptor signaling in prostate cancer.
|
30528321 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
The major topic areas discussed at this year's meeting included (a) new insights into prostate cancer biology and treatment; (b) approaches for accelerating precision medicine for prostate cancer; (c) prostate-specific membrane antigen-targeted therapy and imaging for prostate cancer; (d) updates on Poly (ADP-ribose) polymerase (PARP)-inhibitor clinical trial results; (e) the biology and role of prostate cancer stem cells; (f) new approaches for targeting the androgen receptor and other steroid hormone receptor pathways; (g) racial disparities in prostate cancer treatment and outcomes; (h) the role of the nervous system in prostate cancer development and progression; (i) the role of the WNT signaling pathway in normal prostate and prostate cancer biology; (j) novel immunotherapy approaches; and (k) the ecology of prostate cancer.
|
31334865 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.
|
30629437 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Despite the AR being one of the most studied and attended targets in cancer, those gain-of-function mutations in the receptor remain a significant challenge for the development of PCa therapies.
|
31698174 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling is a key pathway in prostate cancer, and patients are initially treated with androgen deprivation therapy.
|
30848157 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
The results of the present study suggested that miR-381 may act as a tumor suppressor in PCa by directly targeting the AR.
|
31423279 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
|
30106164 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
|
30334814 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer.
|
30763142 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Prostate cancer (PCa) is driven by the androgen receptor (AR)-signaling axis.
|
30776192 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Many genes exhibit evidence for allele-specific transcriptional activation by PrCa master-regulators (including androgen receptor) in Position Weight Matrix, Chip-Seq, and Hi-C experimental data, suggesting common regulatory mechanisms for the associated genes.
|
31308362 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells.
|
30871130 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
To combat treatment resistance, down-regulating AR protein expression has been considered as a potential treatment strategy for CR-PCa.
|
30280407 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Activation of PSGR with β-ionone suppresses prostate cancer progression by blocking androgen receptor nuclear translocation.
|
30928381 |
2019 |
|
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Collectively, this work provides a potential lead compound for anticancer agent development related to prostate cancer therapy, and took a step forward towards the development of novel and improved AR antagonists.
|
31493989 |
2019 |